Trial Profile
Phase II Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Jul 2012 New trial record